Quick Answer
Pulmonx Corp reported R&D Expense of $19.49 million for fiscal year 2025.
Pulmonx Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $19.49M | +10.9% |
| 2024 | $17.57M | -2.8% |
| 2023 | $18.08M | +17.4% |
| 2022 | $15.40M | +17.9% |
| 2021 | $13.06M | +75.1% |
| 2020 | $7.46M | +23.3% |
| 2019 | $6.05M | -13.5% |
| 2018 | $6.99M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.85M | +29.4% | -8.7% |
| June 30, 2025 | $5.31M | -5.5% | +11.6% |
| March 31, 2025 | $4.76M | +13.0% | +27.0% |
| September 30, 2024 | $3.74M | -11.3% | -33.3% |
| June 30, 2024 | $5.62M | -1.7% | +33.4% |
| March 31, 2024 | $4.21M | -1.0% | -0.2% |
| September 30, 2023 | $4.22M | -3.3% | -26.1% |
| June 30, 2023 | $5.71M | +58.9% | +34.3% |
- Pulmonx Corp showed an increase of +10.9% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Pulmonx Corp’s r&d expense has grown by 178.8% (from $6.99 million to $19.49 million).
- The most recent figure is from Pulmonx Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: